- Home
- TSI vs PRME Comparison
TSI vs PRME Comparison
Compare TSI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- PRME
- Stock Information
- Founded
- TSI 1987
- PRME 2019
- Country
- TSI United States
- PRME United States
- Employees
- TSI N/A
- PRME N/A
- Industry
- TSI Investment Managers
- PRME Medicinal Chemicals and Botanical Products
- Sector
- TSI Finance
- PRME Health Care
- Exchange
- TSI Nasdaq
- PRME Nasdaq
- Market Cap
- TSI 234.6M
- PRME 191.7M
- IPO Year
- TSI N/A
- PRME 2022
- Fundamental
- Price
- TSI $4.88
- PRME $4.21
- Analyst Decision
- TSI
- PRME Buy
- Analyst Count
- TSI 0
- PRME 6
- Target Price
- TSI N/A
- PRME $9.38
- AVG Volume (30 Days)
- TSI 106.8K
- PRME 5.8M
- Earning Date
- TSI 01-01-0001
- PRME 08-08-2025
- Dividend Yield
- TSI 7.46%
- PRME N/A
- EPS Growth
- TSI N/A
- PRME N/A
- EPS
- TSI N/A
- PRME N/A
- Revenue
- TSI N/A
- PRME $3,846,000.00
- Revenue This Year
- TSI N/A
- PRME $104.12
- Revenue Next Year
- TSI N/A
- PRME $108.24
- P/E Ratio
- TSI N/A
- PRME N/A
- Revenue Growth
- TSI N/A
- PRME 550.76
- 52 Week Low
- TSI $4.48
- PRME $1.11
- 52 Week High
- TSI $4.87
- PRME $5.95
- Technical
- Relative Strength Index (RSI)
- TSI 44.96
- PRME 60.42
- Support Level
- TSI $4.86
- PRME $3.71
- Resistance Level
- TSI $4.92
- PRME $5.15
- Average True Range (ATR)
- TSI 0.03
- PRME 0.53
- MACD
- TSI 0.00
- PRME -0.06
- Stochastic Oscillator
- TSI 42.86
- PRME 34.25
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.